LDS/Medical Tests/Prenatal RhD NIPT Cell-free DNA Screening (UNITY Fetal Antigen™, Fetal RhD NIPT Panorama™)

Prenatal RhD NIPT Cell-free DNA Screening (UNITY Fetal Antigen™, Fetal RhD NIPT Panorama™)

The Rhesus (Rh) D antigen, encoded by the RhD gene, is among the most immunogenic red cell antigens. When a Rh-negative mother conceives a Rh-positive fetus, maternal exposure to fetal red blood cells during delivery can result in alloimmunization. Maternal anti-D IgG antibodies formed during this process cross the placenta in subsequent pregnancies, attacking fetal Rh-positive red blood cells. This leads to erythroblastosis fetalis and hemolytic disease of the fetus and newborn (HDFN), conditions characterized by fetal anemia, hyperbilirubinemia, kernicterus, hydrops fetalis, and even fetal demise.

To prevent HDFN, Rh immune globulin (RhoGAM) is administered prophylactically to Rh-negative mothers. However, up to 40% of Rh-negative pregnant women carry a Rh-negative fetus, making such prophylaxis unnecessary in those cases. At present, RhoGAM shortages are anticipated to last throughout 2024, further highlighting the need for more targeted administration.

The Prenatal RhD NIPT is a noninvasive screening test performed as early as 7 weeks’ gestation. It analyzes cell-free fetal DNA (cfDNA) in maternal blood to determine the fetal RhD genotype and predict RhD phenotype. UNITY™ and Panorama™ platforms use next-generation sequencing (NGS) for high accuracy, with reported 100% sensitivity and 99.3% specificity. Early fetal RhD determination can help clinicians individualize RhIg administration, minimize unnecessary use, and focus monitoring in alloimmunized pregnancies.

  • Screens for fetal RhD genotype and predicts phenotype
  • Guides RhIg (RhoGAM) administration during pregnancy for non-alloimmunized Rh-negative women
  • Serves as a diagnostic adjunct and monitoring tool in alloimmunized pregnancies

Positive result: RhD gene detected; fetus is predicted to be Rh-positive and at risk for alloimmunization.

Negative result: RhD gene not detected; fetus predicted to be Rh-negative. May result from RhD gene deletion or variant alleles.     

Not Detected (Negative)

Next-generation sequencing (NGS).

Maternal whole blood, EDTA.

Stability

  • Ambient: 3 days
  • Refrigerated: 7 days
Anti-D antibody titer, Indirect antiglobulin test (IAT), ABO and Rh typing, Antibody screen, Amniotic fluid total bilirubin, CBC, Peripheral blood smear (PBS), LDH and reticulocyte count.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login